BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27273830)

  • 21. Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia.
    Garcia-Cuellar MP; Steger J; Füller E; Hetzner K; Slany RK
    Haematologica; 2015 Jul; 100(7):905-13. PubMed ID: 25911551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
    Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
    Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
    Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; Perdonà S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R
    Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
    Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
    Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
    Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
    J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.
    Li T; Huang S; Dong M; Gui Y; Wu D
    Urol Oncol; 2013 Nov; 31(8):1539-45. PubMed ID: 23089540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of store-operated channel components in prostate cancer: the prognostic paradox.
    Perrouin Verbe MA; Bruyere F; Rozet F; Vandier C; Fromont G
    Hum Pathol; 2016 Mar; 49():77-82. PubMed ID: 26826413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PBX3 Promotes Tumor Growth and Angiogenesis via Activation of AT1R/VEGFR2 Pathway in Papillary Thyroid Carcinoma.
    Chen Q; Yu WY; Zhang HH; Zhang SZ; Fang J; Wu F; Ying HZ; Yu CH
    Biomed Res Int; 2020; 2020():8954513. PubMed ID: 32047817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
    Rabien A; Fritzsche FR; Jung M; Tölle A; Diamandis EP; Miller K; Jung K; Kristiansen G; Stephan C
    Int J Cancer; 2010 Nov; 127(10):2386-94. PubMed ID: 20473923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.
    Stein J; Majores M; Rohde M; Lim S; Schneider S; Krappe E; Ellinger J; Dietel M; Stephan C; Jung K; Perner S; Kristiansen G; Kirfel J
    Am J Pathol; 2014 Sep; 184(9):2430-7. PubMed ID: 25016185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asporin is a stromally expressed marker associated with prostate cancer progression.
    Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
    Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Caveolin-1 as a biomarker to predict therapeutic effect of low-frequency ultrasound combined with SonoVue on prostate cancer in nude mice model.
    Xu W; Nan S; Bai W; Shen E; Hu B
    Cancer Biomark; 2014; 14(4):279-86. PubMed ID: 24934371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
    Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
    Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
    Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High level of homeobox A9 and PBX homeobox 3 expression in gastric cancer correlates with poor prognosis.
    Ma YY; Zhang Y; Mou XZ; Liu ZC; Ru GQ; Li E
    Oncol Lett; 2017 Nov; 14(5):5883-5889. PubMed ID: 29113222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer.
    Liao Y; Grobholz R; Abel U; Trojan L; Michel MS; Angel P; Mayer D
    Int J Cancer; 2003 Nov; 107(4):676-80. PubMed ID: 14520710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PBX3 hypermethylation in peripheral blood leukocytes predicts better prognosis in colorectal cancer: A propensity score analysis.
    Sun H; Huang H; Li D; Zhang L; Zhang Y; Xu J; Liu Y; Liu Y; Zhao Y
    Cancer Med; 2019 Jul; 8(8):4001-4011. PubMed ID: 31140752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
    Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.